Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHJ 002

Next Previous
X
Search
Drug Profile

SHJ 002

Alternative Names: Anti-myopia eyedrop - Sun Hawk Vision Biotech; microRNA-328 antisense oligonucleotide - Sunhawk Vision Biotech; miRNA-328 antisense oligonucleotide - Sunhawk Vision Biotech; SHJ-002

Latest Information Update: 04 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sunhawk Vision Biotech
  • Class Antisense oligonucleotides; Eye disorder therapies
  • Mechanism of Action Gene silencing; MicroRNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Corneal disorders; Dry eyes
  • No development reported Myopia

Most Recent Events

  • 30 Aug 2024 Sunhawk Vision Biotech plans a phase II trial for Myopia (Children) in USA (Opthalmic) (NCT06579287)
  • 28 Aug 2024 No recent reports of development identified for phase-I development in Myopia(In adolescents, In children) in Taiwan (Ophthalmic, Drops)
  • 28 Jun 2024 Phase-II clinical trials in Corneal disorders in Taiwan (Ophthalmic) (NCT06381986)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top